Extended Indications for Surgical Sealant

Following the publication of new fibrin sealant guidelines in January 2005, a human surgical sealant is now approved for use in improving hemostasis, where standard surgical techniques are insufficient.

Called Quixil, the sealant was previously only indicated for liver surgery and large-joint replacement where efficacy has been proven. In traditional fibrin sealants, bovine sourced proteins are present. Quixil, however, is the only sealant that is completely free of animal-sourced components. The sealant is ready for application in less than one minute after thawing and is more adherent and flexible than traditional fibrin sealants, even at low temperatures, potentially lowering sepsis rates.

The two-component sealant consists of a biologic active component (BAC)--human clottable protein and tranexamic acid--and thrombin. Each of the components undergoes two separate and different virus activation and removal steps during manufacturing to reduce the risk of transmission of non-enveloped viruses. This also increases the probability of inactivating unidentified pathogens.

Quixil is a registered trademark of Omrix Biopharmaceuticals, S.A. (Brussels, Belgium) and is marketed in the United Kingdom by Johnson & Johnson Wound Management (New Brunswick, NJ, USA).






Related Links:
Johnson & Johnson